- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
834
Companies which are more than 50% undervalued based on analyst price target.
834 companies
CalciMedica
Market Cap: US$27.0m
A clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
CALC
US$2.00
7D
14.3%
1Y
-64.3%
Karolinska Development
Market Cap: SEK 261.5m
A venture capital firm specializing in investments in growth capital, seed stage, and early stage companies.
KDEV
SEK 0.97
7D
7.3%
1Y
-40.2%
OnKure Therapeutics
Market Cap: US$25.8m
A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers.
OKUR
US$1.92
7D
-23.2%
1Y
n/a
Daré Bioscience
Market Cap: US$25.8m
A biopharmaceutical company, develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health in the United States.
DARE
US$2.91
7D
-2.3%
1Y
-21.9%
Corline Biomedical
Market Cap: SEK 248.6m
Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.
CLBIO
SEK 10.15
7D
-2.4%
1Y
0.5%
BioAtla
Market Cap: US$25.1m
A clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
BCAB
US$0.43
7D
-23.0%
1Y
-84.1%
NeuroSense Therapeutics
Market Cap: US$25.0m
A clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.
NRSN
US$1.04
7D
1.3%
1Y
-11.5%
Island Pharmaceuticals
Market Cap: AU$38.9m
A drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America.
ILA
AU$0.18
7D
8.8%
1Y
213.6%
Marinomed Biotech
Market Cap: €21.8m
A biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally.
MARI
€12.25
7D
-1.2%
1Y
-28.4%
Advicenne
Market Cap: €21.7m
A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally.
ALDVI
€1.76
7D
0.8%
1Y
-1.7%
Generation Bio
Market Cap: US$24.1m
A biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells.
GBIO
US$0.36
7D
-17.4%
1Y
-88.0%
Enlivex Therapeutics
Market Cap: US$24.1m
Operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
ENLV
US$1.02
7D
-1.9%
1Y
-32.0%
Chemomab Therapeutics
Market Cap: US$23.8m
A clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.
CMMB
US$1.26
7D
-11.3%
1Y
50.2%
IGC Pharma
Market Cap: US$23.7m
A clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease.
IGC
US$0.30
7D
-1.3%
1Y
-42.1%
AlzeCure Pharma
Market Cap: SEK 227.8m
Operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
ALZCUR
SEK 2.58
7D
5.3%
1Y
50.4%
SynBiotic
Market Cap: €20.5m
Engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety.
SBX
€3.01
7D
0%
1Y
-66.2%
Tempest Therapeutics
Market Cap: US$22.7m
A clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various cancers.
TPST
US$6.49
7D
-7.2%
1Y
-84.6%
Clene
Market Cap: US$22.7m
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
CLNN
US$2.63
7D
-11.7%
1Y
-66.0%
DURECT
Market Cap: US$22.7m
A biopharmaceutical company, develops medicines based on its epigenetic regulator program.
DRRX
US$0.73
7D
22.1%
1Y
-31.1%
ALX Oncology Holdings
Market Cap: US$22.6m
A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
ALXO
US$0.42
7D
-20.8%
1Y
-97.4%
Little Green Pharma
Market Cap: AU$34.9m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.12
7D
-8.0%
1Y
-11.5%
KALA BIO
Market Cap: US$22.1m
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases.
KALA
US$3.42
7D
-8.8%
1Y
-50.4%
Lexaria Bioscience
Market Cap: US$21.0m
Operates as a biotechnology company.
LEXX
US$1.08
7D
-9.2%
1Y
-69.6%
Scilex Holding
Market Cap: US$21.0m
Focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
SCLX
US$4.01
7D
-26.3%
1Y
-84.6%
CollPlant Biotechnologies
Market Cap: US$20.8m
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
CLGN
US$1.82
7D
-15.4%
1Y
-72.5%
CEL-SCI
Market Cap: US$20.8m
A clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
CVM
US$0.25
7D
-1.7%
1Y
-82.6%
BioVie
Market Cap: US$20.7m
A clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease.
BIVI
US$1.12
7D
-7.4%
1Y
-77.0%
Ovid Therapeutics
Market Cap: US$20.6m
A biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
OVID
US$0.29
7D
-10.4%
1Y
-90.3%
ImmunoPrecise Antibodies
Market Cap: US$20.5m
Operates as a techbio company.
IPA
US$0.45
7D
-2.2%
1Y
-65.2%
Jupiter Neurosciences
Market Cap: US$20.5m
A clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation.
JUNS
US$0.62
7D
-3.1%
1Y
n/a
MIRA Pharmaceuticals
Market Cap: US$20.5m
Operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
MIRA
US$1.22
7D
5.2%
1Y
69.4%
Passage Bio
Market Cap: US$20.5m
A genetic medicines company, develops gene therapies for central nervous system diseases.
PASG
US$0.33
7D
-16.7%
1Y
-77.6%
Elevation Oncology
Market Cap: US$20.3m
An oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
ELEV
US$0.34
7D
-2.0%
1Y
-89.5%
Annexin Pharmaceuticals
Market Cap: SEK 196.1m
A biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases.
ANNX
SEK 0.28
7D
-3.8%
1Y
-12.9%
Medivir
Market Cap: SEK 194.9m
A pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally.
MVIR
SEK 1.74
7D
4.3%
1Y
-43.9%
Longeveron
Market Cap: US$20.0m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$1.34
7D
-14.1%
1Y
-7.9%